Anika Therapeutics (ANIK) Misses Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.87 --0%
Revenue Growth %: +5.5%
Financial Fact:
Total revenue: 25.79M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +5.5%
Financial Fact:
Total revenue: 25.79M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.37, $0.01 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $23.4 million versus the consensus estimate of $23.89 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
- Seven Hills Realty Trust (SEVN) Reiterated at Market Outperform by Citizens Post Q2 Results
- Morgan Stanley Upgrades Mitsubishi Chemical Holdings (4188:JP) (MTLHY) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
